IL18 and triple-negative breast carcinoma: Of particular clinical relevance, Park's research group demonstrated that IL-18 contributes to the adverse prognostic outcomes in triple-negative breast cancer patients through a novel immunosuppressive mechanism involving PD-1 receptor upregulation on NK cells, thereby attenuating antitumor immunity [25].